Inprosub (Progesterone)

Progesterone binds to intracellular progesterone receptors, altering gene transcription. This prepares the uterine lining for embryo implantation, maintains uterine quiescence during pregnancy, and provides anti‑estrogenic effects that help regulate the menstrual cycle and support hormone replacement therapy.

The specific dose and dosing schedule of Inprosub are determined by the prescribing clinician based on the indication, patient characteristics, and treatment protocol. No fixed regimen is provided here.

Progesterone is used in certain pregnancy situations, such as luteal phase support and preterm‑birth prevention, but safety must be evaluated by the treating physician. Limited data are available for breastfeeding, and a clinician should assess risk versus benefit.

To order Inprosub, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Inprosub is an injectable progesterone formulation, offering rapid systemic exposure compared with oral micronized progesterone, which undergoes first‑pass metabolism. Injectable routes provide more consistent serum levels, which can be advantageous for luteal support and preterm‑birth prevention, while oral forms are more convenient but may have variable absorption.

Inprosub must be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep the product in its original packaging until use to maintain stability.

Inprosub is administered by a healthcare professional via intramuscular or subcutaneous injection, according to the prescribing information. The injection site and technique are selected based on the clinical protocol and patient tolerance.

Serious risks include rare thromboembolic events, severe allergic reactions such as anaphylaxis, hyperglycemia, and hepatic dysfunction. Patients should be monitored for signs of clotting, hypersensitivity, abnormal liver tests, or significant changes in blood glucose.

Inprosub should be avoided in individuals with known hypersensitivity to progesterone, active breast or endometrial cancer, uncontrolled thromboembolic disorders, and in patients where hormonal therapy is contraindicated. A clinician must evaluate each patient’s medical history before prescribing.